{"id":57988,"date":"2026-02-26T13:09:09","date_gmt":"2026-02-26T05:09:09","guid":{"rendered":"https:\/\/flcube.com\/?p=57988"},"modified":"2026-02-26T13:09:10","modified_gmt":"2026-02-26T05:09:10","slug":"lepu-biopharmas-gpc3-adc-mrg006a-wins-nmpa-approval-for-hcc-combination-trials-first-in-class-asset-advances","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57988","title":{"rendered":"Lepu Biopharma’s GPC3 ADC MRG006A Wins NMPA Approval for HCC Combination Trials \u2013 First\u2011in\u2011Class Asset Advances"},"content":{"rendered":"\n

Lepu Biopharma Co., Ltd (HKG:\u202f2157<\/a>)<\/strong> announced that China’s National Medical Products Administration (NMPA)<\/strong> has approved MRG006A<\/strong>, its independently developed antibody\u2011drug conjugate (ADC)<\/strong>, to initiate clinical trials for advanced hepatocellular carcinoma (HCC)<\/strong> in combination with immune checkpoint inhibitors and targeted therapeutic agents<\/strong>. The GPC3\u2011targeted ADC<\/strong> with first\u2011in\u2011class (FIC) potential<\/strong> builds on promising monotherapy data and FDA Orphan Drug Designation<\/strong> secured in December\u202f2025.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Lepu Biopharma Co., Ltd (HKG:\u202f2157)<\/td><\/tr>
Product<\/strong><\/td>MRG006A<\/td><\/tr>
Drug Class<\/strong><\/td>GPC3\u2011targeted antibody\u2011drug conjugate (ADC)<\/td><\/tr>
Platform<\/strong><\/td>Hi\u2011TOPi next\u2011generation ADC technology<\/td><\/tr>
Innovation Status<\/strong><\/td>First\u2011in\u2011class (FIC) potential<\/td><\/tr>
Regulatory Action<\/strong><\/td>NMPA approval for combination trial in HCC<\/td><\/tr>
Combination Partners<\/strong><\/td>Immune checkpoint inhibitors + targeted agents<\/td><\/tr>
Prior Approvals<\/strong><\/td>Monotherapy IND approved (China + US)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Progress<\/h2>\n\n\n\n
Milestone<\/th>Detail<\/th><\/tr><\/thead>
Monotherapy Status<\/strong><\/td>IND approved in China and United States<\/td><\/tr>
Dose\u2011Escalation Results<\/strong><\/td>Exceeded expectations; clear therapeutic efficacy signals<\/td><\/tr>
FDA Designation<\/strong><\/td>Orphan Drug Designation (ODD)<\/strong> granted Dec\u202f2025 for HCC<\/td><\/tr>
New Development<\/strong><\/td>Combination trial with IO + targeted therapy approved<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile \u2013 MRG006A<\/h2>\n\n\n\n
Feature<\/th>Detail<\/th><\/tr><\/thead>
Target<\/strong><\/td>GPC3 (glypican\u20113)<\/strong> \u2013 highly expressed on HCC cells, minimal normal tissue expression<\/td><\/tr>
Class<\/strong><\/td>ADC based on Hi\u2011TOPi platform<\/strong><\/td><\/tr>
Platform Advantages<\/strong><\/td>Next\u2011generation linker\u2011payload technology with enhanced stability and tumor selectivity<\/td><\/tr>
Mechanism<\/strong><\/td>GPC3\u2011mediated internalization \u2192 intracellular payload release \u2192 tumor cell killing<\/td><\/tr>
Differentiation<\/strong><\/td>First\u2011in\u2011class GPC3\u2011targeted ADC in clinical development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n